This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Steroid use and cardiovascular risk (CV risk)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases

  • glucocorticoids (steroids) are widely used to reduce disease activity and inflammation in patients with a range of immune-mediated inflammatory diseases, such as rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, and inflammatory bowel disease
    • however, prolonged glucocorticoid treatment often causes adverse events, including cardiovascular diseases (CVDs) (1,2,3)
      • in SLE, both recent use of corticosteroids and recent lupus activity are independently associated with higher values of several well-recognized CHD risk factors (1)
      • treatment with high-dose glucocorticoids seemed to be associated with increased risk for cardiovascular disease (2)
  • widely recognised that high-dose steroids may increase the risk of cardiovascular disease (CVD; heart disease, stroke, or other vascular diseases), but it is debated whether this increase also applies to lower steroid doses

Study summary:

  • Pujades-Rodriguez et al conducted a population-based cohort analysis of medical records from 389 primary care practices contributing data to the United Kingdom Clinical Practice Research Datalink (CPRD), linked to hospital admissions and deaths in 1998-2017
    • estimated time-variant daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard ratios (HRs) of first all-cause and type-specific cardiovascular diseases (CVDs)
    • were 87,794 patients with giant cell arteritis and/or polymyalgia rheumatica (25,581), inflammatory bowel disease (27,739), rheumatoid arthritis (25,324), systemic lupus erythematosus (3,951), and/or vasculitis (5,199), and no prior CVD
    • mean age was 56 years and 34.1% were men
    • median follow-up time was 5.0 years, and the proportions of person–years spent at each level of glucocorticoid daily exposure were 80% for non-use, 6.0% for <5 mg, 11.2% for 5.0-14.9 mg, 1.6% for 15.0-24.9 mg, and 1.2% for >=25.0 mg.

Study results:

  • in 87,794 adults with immune-mediated inflammatory diseases and no prior CVD (5-year median follow-up), studied the risk of 6 common CVDs associated with the steroid dose prescribed, quantified either as current or as cumulative dose
  • found strong dose-dependent risks of all CVDs, including myocardial infarction, heart failure, atrial fibrillation, and cerebrovascular disease, in patients diagnosed with the 6 inflammatory diseases studied
  • one-year cumulative risks of all-cause CVD increased from 1.4% in periods of non-use to 8.9% for a daily prednisolone-equivalent dose of >=25.0 mg
    • five-year cumulative risks increased from 7.1% to 28.0%, respectively
    • compared to periods of non-glucocorticoid use, those with <5.0 mg daily prednisolone-equivalent dose had increased all-cause CVD risk (HR = 1.74; 95% confidence interval [CI] 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.82 for systemic lupus erythematosus)
    • increased dose-dependent risk ratios were found regardless of disease activity level and for all type-specific CVDs
    • HRs for type-specific CVDs and <5.0-mg daily dose use were: 1.69 (95% CI 1.54-1.85) for atrial fibrillation, 1.75 (95% CI 1.56-1.97) for heart failure, 1.76 (95% CI 1.51-2.05) for acute myocardial infarction, 1.78 (95% CI 1.53-2.07) for peripheral arterial disease, 1.32 (95% CI 1.15-1.50) for cerebrovascular disease, and 1.93 (95% CI 1.47-2.53) for abdominal aortic aneurysm.
  • after 1 year, the overall absolute risk of CVD doubled for individuals using less than 5 mg prednisolone per day and was 6 times higher for users of 25 mg or greater
  • many individuals had known modifiable cardiovascular risk factors, including current smoking (24%), obesity (25%), or hypertension (25%).

Study authors concluded:

  • it was previously believed that less than 5 mg of prednisolone was safe long term, but even at this "low dose" patients with immune-mediated inflammatory diseases have a doubling of their underlying risk of CVD


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.